Anti-Depression Devices & Therapy Market - Forecast to 2026

Fisher Wallace, Boston Scientific Corporation, Neuro-Fitness LLC, Brainsway Ltd, Electromedical Products International, Inc., Sorterix Medical Inc, MagVenture A/S, Flow Neuroscience, Alpha-Stim, Pear Therapeutics, Neuronetics, CervelNeurotech, Magstim, Limbix, NeuroSigma, Vagus nerve stimulation, Koa Health, Sentio, and Cervella are among major participants in the industry.


Brooklyn, New York, April 15, 2021 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Anti-Depression Devices & Therapy Market will grow with a high CAGR value during the forecast period [2021 to 2026].

Anti-Depression Devices & Therapy are an advanced technology group that consistently works on improving people’s mental health. The industry consists of numerous gadgets and therapies to address various mental illnesses caused by different reasons. Increasing incidences of depression among the young and geriatric population due to stressful lifestyles and habits have instigated the demand for anti-depression devices & therapy.

Change in living style such as preference for voluntary isolation, shifting parents to old age homes, and nuclear family trends have resulted in prolonged depression among a large number of the population. Other causes such as hereditary depression, accidents, and death of a family member may also impact the mental health of people. The introduction of these gadgets to overcome mental illness and disorder will advance the overall healthcare industry. Government support and regulations to prevent suicide and crimes caused by mental disorders will stimulate the anti-depression devices & therapy market growth.  


Browse TOC on “Global Anti-Depression Devices & Therapy Market - Forecast to 2026" 

https://www.globalmarketestimates.com/market-report/global-anti-depression-devices-therapy-market-2993


Emergence of virtual reality and artificial intelligence in rehabilitation therapies

Technological advancement in rehabilitation therapies has instigated the adoption of virtual reality and artificial intelligence tools to treat patients. Updated gadgets such as headsets are becoming a trend in anti-depression therapies. They are effective, time-saving, and more protective methodologies rather than the conventional ones. Increased focus towards improved results, time management, and better turnaround time has fueled the anti-depression devices & therapy market.

Helmets or headsets are high in demand

Gadgets such as helmets or headsets are expected to witness the highest gains in the coming years. Customized therapies along with more privacy are major factors driving demand in this segment. Also, it proved to be more effective as compared to medications, and having a long-term positive impact on the patient’s mental health will stimulate the product penetration.

North America being the major contributor

The North America anti-depression devices & therapy market holds the largest share in the regional segment. The U.S. and Canada being the major contributor during the forecast period. Wide consumer awareness about mental health programs along with increasing acceptance towards taking anti-depression therapies has supported the regional growth. Government support to sponsor mental health programs will induce growth as well.

Industry share is competitive and fragmented in nature

Key industry participants include Boston Scientific Corporation, Fisher Wallace, Brainsway Ltd, Neuro-Fitness LLC, Electromedical Products International, MagVenture A/S, Sorterix Medical, Flow Neuroscience, Neuronetics, Cervel Neurotech, Magstim, Limbix, Alpha-Stim, Pear Therapeutics, NeuroSigma, Koa Health, Sentio, Cervella, and Vagus nerve stimulation.


Browse the Report @ https://www.globalmarketestimates.com/market-report/global-anti-depression-devices-therapy-market-2993


Product Outlook (Revenue, USD Million, 2019-2026)

  • Light Therapy
  • Stimulation Therapies
  • Electro Stimulator Devices
  • Helmet Therapy
  • Others

Type Outlook (Revenue, USD Million, 2019-2026)

  • Psychotic Depression
  • Persistent Depressive Disorder
  • Postpartum Depression
  • Major Depression
  • Seasonal Affective Disorder
  • Others

End-Use Outlook (Revenue, USD Million, 2019-2026)

  • Hospitals
  • Homecare Setting
  • Long Term Centers
  • Out Patient Settings   

Regional Outlook (Revenue, USD Million, 2019-2026)

North America                                                                                 

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa


Website: Global Market Estimates

 

Contact Data